


7-2017

# Maternal Undernutrition and Long-term Effects on Hepatic Function

Daniel B. Hardy

*Physiology and Pharmacology*, [daniel.hardy@schulich.uwo.ca](mailto:daniel.hardy@schulich.uwo.ca)

Follow this and additional works at: <https://ir.lib.uwo.ca/physpharmpub>

 Part of the [Medical Physiology Commons](#), [Pharmacy and Pharmaceutical Sciences Commons](#), and the [Reproductive and Urinary Physiology Commons](#)

---

## Citation of this paper:

Hardy, Daniel B., "Maternal Undernutrition and Long-term Effects on Hepatic Function" (2017). *Physiology and Pharmacology Publications*. 99.

<https://ir.lib.uwo.ca/physpharmpub/99>

**Chapter 9** 1  
**Maternal Undernutrition and Long-Term Effects** 2  
**on Hepatic Function** 3

**AUI** **Daniel B. Hardy** 4

**Key Points**

- This chapter focuses on human and animal data linking undernutrition in utero (i.e., placental insufficiency, nutrient restriction, maternal low protein) with long-term hepatic dysfunction in postnatal life.
- Undernutrition in utero influences lipid homeostasis, gluconeogenesis, insulin sensitivity, drug metabolism, and overall growth leading to liver fibrosis and long-term symptoms of the metabolic syndrome.
- Some of the direct mechanisms linking undernutrition in perinatal life to hepatic dysfunction include hypoxia and epigenetic influences (i.e., DNA methylation, posttranslational histone modifications, and microRNAs).
- Rapid postnatal catch-up growth can indirectly augment hepatic ER stress leading to impaired insulin signaling and alterations in microRNAs in the liver.
- Animal studies have indicated that intervention in perinatal life with essential nutrients, hormones, or modulators of nuclear receptors can rescue hepatic gene expression and may prevent the long-term metabolic deficits associated with the undernourished liver.

**Keywords** DOHaD • Epigenetics • Maternal low-protein diet • Hypoxia • Uterine ligation • Nuclear 5  
 receptors • Posttranslational histone modifications • DNA methylation • Endoplasmic reticulum stress 6  
 • MicroRNAs 7

**Abbreviations** 8

11 $\beta$ -HSD1	11 $\beta$ -hydroxysteroid dehydrogenase type 1	9
ADP	Adenine diphosphate	10
Akt1	Protein kinase B	11

---

Supported by: CIHR Operating Grant and Natural Sciences and Engineering Research Council of Canada.

D.B. Hardy (✉)

The Departments of Obstetrics & Gynecology and Physiology & Pharmacology, The Children's Health Research Institute and the Lawson Health Research Institute, The University of Western Ontario, London, ON, Canada  
 e-mail: [Daniel.Hardy@schulich.uwo.ca](mailto:Daniel.Hardy@schulich.uwo.ca)

12	CpG	Cysteine-phosphate-guanine
13	CVD	Cardiovascular disease
14	Cyp2c11	Cytochrome P450 2c11
15	Cyp3a1	Cytochrome P450 3a1
16	Cyp7a1	Cytochrome P450 7a1
17	EPO	Erythropoietin
18	ER stress	Endoplasmic reticulum stress
19	Ex-4	Exendin-4
20	G6Pase	Glucose-6 phosphatase
21	GLP-1	Glucagon-like peptide-1
22	GR	Glucocorticoid receptor
23	HDL	High-density lipoproteins
24	IGF-1	Insulin growth factor 1
25	IUGR	Intrauterine growth restriction
26	JMJD	Jmj domain-containing histone demethylation protein
27	LDL	Low-density lipoproteins
28	LP	Low protein
29	LXR	Liver X receptor
30	miRs	MicroRNAs
31	MMP2	Matrix metalloproteinase 2
32	MNR	Maternal nutrition restriction
33	MPR	Maternal protein restriction
34	pAkt1 (Ser473)	Phospho Akt1 (serine 473)
35	Pck1	Phosphoenolpyruvate carboxykinase 1 (soluble)
36	pEIF2 $\alpha$	Phospho-eukaryotic translation initiation factor 2
37	PND	Postnatal day
38	PPAR	Peroxisome proliferator-activated receptor
39	SGA	Small for gestational age
40	SMAD4	SMAD family member 4
41	TGFB1	Transforming growth factor $\beta$ 1
42	TUDCA	Tauroursodeoxycholic acid
43	UPR	Unfolded protein response
44	VEGF	Vascular endothelial growth factor

## 45 Introduction

[AU2](#)

46 The liver plays a critical role in mammals for metabolism, digestion, detoxification, storage, protein  
 47 production, and immunity. Given the role of the liver in cholesterol, fatty acid, and glucose homeosta-  
 48 sis, it is not surprising hepatic dysfunction underlies several of the symptoms (i.e., hypercholesterol-  
 49 emia, obesity, glucose intolerance) characterizing the metabolic syndrome [1, 2]. The surge in the  
 50 incidence of the metabolic syndrome worldwide is of great concern considering that it raises the risk  
 51 of developing cardiovascular disease (CVD) by ~20-fold, and CVD is responsible for 1 out 2.9 deaths  
 52 in the United States [3–6]. In addition to the metabolic syndrome, impaired liver health and function  
 53 also can lead to liver fibrosis (and the end-stage cirrhosis), which is estimated to contribute up to 45%  
 54 of deaths in the developed world [7, 8]. Liver fibrosis is a major predictor for diabetes, overall liver  
 55 failure, portal hypertension, and liver cancer [9–11]. Since diet (i.e., “Western diet”) is a major con-  
 56 tributor to defects in liver function and ultimately liver fibrosis or CVD, current therapeutic strategies  
 57 are aimed at lifestyle modifications (i.e., physical activity and healthy eating) and/or pharmaceutical  
 58 interventions to treat the disease once manifested [12–15]. While pharmaceuticals may be effective

reducing the risk of CVD, the long-term dependency on them can be dangerous for the liver. For example, statins can reduce the risk of ischemic heart disease by up to 60%; however, the existence of statin-induced rhabdomyolysis and hepatitis-associated liver failure emerges in some patients [16]. Clearly additional studies are warranted for hepatic disease prevention versus treatment. A major preventative strategy is in recognizing the early origins of adult disease so that efficacious interventions can be targeted to prevent long-term defects in liver function.

**Maternal Undernutrition and Impaired Hepatic Function: Clinical Evidence**

Over 25 years ago, Professor David Barker revealed that adverse in utero events can permanently alter physiological processes leading to the metabolic syndrome [17]. The early evidence that an impairment of liver size and/or function was involved came from the fact that there was a strong correlation between reduced abdominal circumference at birth with elevated total and LDL cholesterol in adulthood [18]. Secondly, intrauterine growth restriction (IUGR), caused by either placental insufficiency or maternal malnutrition, often results in asymmetric organ development whereby there is a reduction in the growth of less essential organs such as the liver, lungs, and kidneys [19, 20]. Thirdly, there is a strong inverse relationship between birth weight and obesity or glucose intolerance; both under the regulation of the liver [21–24]. It is noteworthy that the majority of these links to metabolic disease arose from large population-based studies whereby under nutrition in utero (i.e., due to famine) was the major factor leading to impaired fetal growth [21, 25–28].

Postpartum, the major factor influencing this inverse relationship between low birth weight and metabolic disease is nutrition-induced accelerated growth in neonatal life, which leads to an earlier onset of the symptoms of the metabolic syndrome [25, 29–31]. Barker explained this phenomenon with the “predictive adaptive response” hypothesis, which suggests that “adverse events during development induce adaptations suited for survival in a similar predictive environment but can become maladaptive if a mismatch to the predictive environment occurs, leading to a thrifty phenotype” [32, 33]. Since IUGR leads to major decreases in fetal liver development, it seems conceivable that the liver has the most to gain in growth during postnatal life [19, 20]. Animal models of IUGR support that the undernourished liver undergoes rapid postnatal catch-up growth leading to further metabolic dysfunction, but there is evidence from human studies as well [34–36]. For example, infants born small for gestational age (SGA) undergo hypersomatotropism as early as 4 days as a result of increased circulating insulin growth factor 1 (IGF-1) produced by the liver [37]. Elegant studies by Singhal et al. have also demonstrated that low birth weight infants with rapid postnatal growth (due to growth-promoting formula diets) exhibited a higher LDL/HDL ratio, likely derived from impaired cholesterol homeostasis in the liver [38]. While future noninvasive imaging studies are warranted to tract liver development (i.e., liver growth, lipid composition) in IUGR infants long-term, animal models of maternal undernutrition have shed great light into the mechanisms underlying the fetal programming of the liver. More importantly, by elucidating some of the underlying mechanisms involved, new pharmaceutical and dietary intervention strategies can be employed to prevent these defects in liver function.

**Uterine Ligation or Ablation Model of Undernutrition and Long-Term Hepatic Function**

As previously mentioned, IUGR can occur due to placental insufficiency which occurs in about 8% of pregnancies [39, 40]. Animal studies have demonstrated that placental insufficiency-induced IUGR leads to decreases in oxygenation and substrate availability for the fetus [41–43]. Therefore, the uterine ligation or uterine ablation serves as an excellent model for examining idiopathic IUGR and the

102 short- and long-term effects on liver function. Both models lead to decreased birth weight and lower  
103 liver to body weight ratios [35, 44]. In the guinea pig, uterine ablation led to a greater incidence of  
104 hepatic perisinusoidal or periportal fibrosis in 5-month offspring with increased expression of profi-  
105 brogenic markers including TGF $\beta$ 1, MMP2, and SMAD4 [44]. In rats, uterine ligation leads to devel-  
106 opment of the metabolic syndrome in the offspring including type 2 diabetes, dyslipidemia, and  
107 hypertriglyceridemia [45–47]. Interestingly, many of these symptoms were reciprocated into the F2  
108 generation [48]. These metabolic deficits exist, in part, due to altered glucose transporter expression,  
109 impairment of fatty acid metabolism, increased glucocorticoid activity, augmented glucose produc-  
110 tion, and blunted insulin suppression all within the liver [45, 47, 49–51]. These offspring also exhib-  
111 ited decreased hepatic and circulating insulin growth factor 1 (Igf-1) which is critical for insulin  
112 function, glucose metabolism, and growth [52]. While other models of maternal dietary-induced  
113 IUGR led to hypercholesterolemia in postnatal life, uterine ligation appears to have no effect on cho-  
114 lesterol homeostasis unless the offspring were challenged with a high-fat diet in postnatal life [34, 53,  
115 54]. Although this animal model is physiologically relevant to idiopathic IUGR, it is distinct from  
116 dietary-induced undernutrition as it leads to direct decreases in both oxygen and nutrients to the fetus.  
117 Other exclusive dietary models are essential in understanding the contribution of maternal malnutri-  
118 tion alone on long-term hepatic function and disease.

### 119 **Maternal Nutrient Restriction (MNR) Model of Undernutrition**

120 Human and animal studies of food restriction during pregnancy confirm that maternal undernourish-  
121 ment leads to IUGR depending upon the timing (pre- vs postconception) and severity of the insult [28,  
122 29, 55–57]. Moreover, like models of uterine ligation, fetal liver growth from MNR dams is compro-  
123 mised at birth followed by rapid postnatal catch-up growth [36, 55, 58]. However, with models of  
124 MNR, the impact of a decrease in maternal and placental weight during pregnancy must also be taken  
125 into consideration [55, 59]. Sheep and rat studies have demonstrated that MNR leads to glucose intoler-  
126 erance and insulin insensitivity, along with greater hepatic lipid and glycogen content in the offspring  
127 [58, 60]. The impaired glucose tolerance in MNR sheep offspring is attributed, in part, to increased  
128 circulating cortisol and augmented hepatic PEPCK expression in MNR offspring [60]. In contrast to  
129 offspring of uterine ligation, MNR offspring with catch-up growth exhibited increases in Igf-1 which  
130 the authors attribute is associated with decreased longevity, but not necessarily metabolic disease [58].

### 131 **Maternal Protein Restriction (MPR) Model of Undernutrition**

132 Placental insufficiency in humans often leads to protein (and amino acid) deficiencies in the fetus,  
133 which are critical for fetal growth [61, 62]. Therefore, the MPR model is a relevant model to study  
134 placental insufficiency-IUGR as it leads to asymmetric IUGR, without any effects on maternal weight  
135 gain or food intake [22, 63]. Moreover, MPR offspring have decreases in fetal liver weight at birth and,  
136 depending on the timing of protein restoration, display liver and whole body catch-up growth despite  
137 no differences in food intake [34, 64]. Remarkably, MPR offspring, more predominantly in males,  
138 exhibit several symptoms of the metabolic syndrome including glucose intolerance, visceral obesity,  
139 hypercholesterolemia, and hypertension [34, 65–69]. The glucose intolerance is attributed to augmented  
140 gluconeogenesis (e.g., G6Pase, 11 $\beta$ -HSD1), diminished glucokinase expression, decreased pAkt1  
141 (Ser473), and decreased glucagon receptor in the livers of MPR offspring [64, 67, 70, 71]. With respect  
142 to lipids, MPR male offspring with catch-up growth show increases in circulating hepatic cholesterol  
143 due to decreases in the expression of Cyp7a1, the critical enzyme in cholesterol metabolism [34].  
144 Aside from alterations in glucose and cholesterol homeostasis, MPR male offspring with catch-up also

exhibit increases in hepatic Cyp3a and Cyp2c11 expression and activity influencing long-term drug metabolism (i.e., statins) in these offspring [72]. As testosterone is a major substrate for these Cyp enzymes, it may explain why MPR male offspring have lower circulating testosterone levels, and consequently, the long-term sexual dimorphism which exists in this model [68]. Similar to uterine-ligated offspring, MPR offspring with catch-up growth have decreases in hepatic Igf-1; however, the decrease in Igf-1 is mainly attributed to the effects of protein restriction during lactation [63]. All in all, the MPR model truly reinforces the main principle of Barker's "predictive adaptive response" given that when there is no nutritional mismatch in postnatal life, MPR offspring do not exhibit any decreases in cholesterol catabolism, insulin sensitivity, or drug metabolism in the liver [34, 64, 72].


## Direct Mechanisms Linking Maternal Undernutrition and Adverse Metabolic Outcomes

While human and animal studies have certainly established the strong links between an undernourished in utero environment and metabolic deficits in the offspring, we only just beginning to unravel the direct and indirect molecular events involved. Interestingly, one of the major direct drivers of altered hepatic gene expression and function short- and long-term would be hypoxia. While it is not surprising that uterine ligation directly leads to hypoxia in the liver, maternal undernutrition alone in guinea pigs also led to increases in the expression of markers of hypoxia (EPO, EPO receptor, VEGF) in the fetal liver and kidney [35, 73]. In uterine ligation studies, decreases in oxygenation reduced hepatic mitochondrial oxidative phosphorylation and further led to oxidative stress in young rat offspring [35, 47]. Collectively, this explains the increased hepatic gluconeogenesis and impaired insulin signaling exhibited in this young offspring.

Epigenetic forces have also been implicated to play a direct and sustaining role in the fetal programming of the liver. Epigenetic mechanisms, which include direct DNA methylation, posttranslational histone modifications, and microRNAs (miRs), influence the long-term expression of a gene by altering the ability of the transcriptional machinery to interact with the chromatin environment. Elegant studies in the baboon fetus have demonstrated that 70% undernutrition during pregnancy led to augmented hepatic gluconeogenesis associated with both increased *Pck1* mRNA and decreases in the methylation of CpG dinucleotides of the *Pck1* promoter [59]. Moreover, uterine ligation has been shown to directly increase DNA methylation in the promoter of hepatic *Igf-1* at birth and that this persists into the F2 generation even when F1 IUGR offspring are adequately nourished [48, 74]. Interestingly, in this study, supplementation of the diet in the F1 IUGR offspring with folic acid, choline, betaine, vitamin B<sub>12</sub>, and other essential nutrients prevented the methylation of the *Igf-1* promoter in the F2 generation along with symptoms of the metabolic syndrome [48]. However, caution is necessary in the overall interpretation of these studies given undernutrition-induced alterations in DNA methylation can vary between sexes and within different CpG islands of the same promoter [74].

Posttranslational histone modifications, which include methylation, acetylation, phosphorylation, ubiquitination, and ADP-ribosylation of histones, serve as another epigenetic mechanism to influence long-term gene expression by perinatal undernutrition. This is evident when maternal dietary protein is restricted during pregnancy and lactation leading to long-term hypercholesterolemia as a result of decreased expression of hepatic *Cyp7a1*, the critical enzyme involved in cholesterol catabolism [34]. Remarkably, the histone modifications involved in MPR-induced silencing the expression of *Cyp7a1* promoter, namely, increased trimethylation and decreased acetylation of histone H3 [lysine 9, 14], are sustained from 3 weeks to 4 months in postnatal life [34]. The origin of these histone modifications is due, in part, to MPR-mediated decreased in *Jmjd2a* and *Jmjd2c*, demethylases involved in removing trimethyl groups of histone H3 [lysine 9]. It is noteworthy that while both male and female MPR offspring exhibited decreased *Cyp7a1* expression at 3 weeks, female MPR offspring at 4 months are protected from the posttranslational histone modifications silencing the *Cyp7a1* promoter. MPR has

192 also been demonstrated to lead to long-term posttranslational histone modifications (e.g., decreased  
 193 histone H3 acetylation [lysine 9, 14] silencing the expression of the hepatic liver X receptor (*LXR $\alpha$* )  
 194 at 4 months (Fig. 9.1) [67]. The decrease in the expression of this repressive glucose sensor permitted



**Fig. 9.1** The effect of maternal low-protein diet in utero on the in vivo transcriptional and epigenetic regulation of the *LXR $\alpha$*  transcriptional start site (-135 to +144 bp) at 4 months of age. (a) Binding of RNA polymerase II to the *LXR $\alpha$*  TSS, (b) trimethylation of histone H3 lysine 4, (c) acetylation of histone H3 lysine 9 and 14, and (d) trimethylation of histone H3 lysine 9. Primers were designed based on sequencing from *Ensembl*. Livers were immunoprecipitated with antibodies specific to RNA polymerase II, trimethylated histone H3 [K4], acetylated histone H3 [K9, 14], and trimethylated histone H3 [K9]. Quantification was performed using qRT-PCR (*Sso-Fast EvaGreen*) with primers specific to the proposed *LXR* element sites. The relative amount of immunoprecipitated genomic DNA was normalized to total genomic DNA. Data are represented as arbitrary values using the  $\Delta\Delta$ Ct method. Results are expressed as the mean  $\pm$  standard error (SEM). \* = Statistically significant.  $n = 4-6$  (Reprinted from Vo et al. [67], with permission from BioScientifica Ltd.)

augmented expression of hepatic gluconeogenic enzymes (e.g., G6Pase and 11 $\beta$ -HSD1) contributing to glucose intolerance [67].

MiRs, which consist of short, noncoding RNA molecules of 20–25 nucleotides in length, can also act in an epigenetic manner to regulate gene expression by repressing the translation of proteins or decreasing messenger RNA (mRNA) stability. MPR during pregnancy and lactation has been demonstrated to increase the expression of miR-29a, miR-29b, and miR-29c in the liver by 3 weeks and 4 months of age which silences the expression of Igf-1 and decreases body weight [63]. Interestingly, protein restriction during lactation alone had a greater effect to augment the miR-29 family and suppress Igf-1, while restoration of maternal dietary proteins in MPR offspring at birth prevented miR-29 repression of Igf-1 [63]. In the guinea pig, uterine ligation in pregnancy led to decreases in hepatic miR-146a expression in the 5-month offspring, concomitant with an increase in its target profibrotic gene, SMAD4 [44]. Further studies are warranted to investigate how the expression of miRs in the liver is altered by perinatal undernutrition via direct (i.e., regulation of 5'-UTR of miR promoters) and indirect (i.e., ER stress) mechanisms [75].


## Indirect Mechanisms Linking Maternal Undernutrition and Adverse Metabolic Outcomes: The Contribution of Catch-Up Growth

In several animal models of maternal undernutrition leading to metabolic disease, often the changes in hepatic gene expression do not occur directly at the time of the perinatal insult but manifests later in life [58, 64, 72]. This may be attributed to long-term global changes (e.g., epigenetic mechanisms), initiated by the perinatal environment, which precedes the eventual alterations in gene function. For example, in MPR offspring whereby increases in trimethylation of histone H3 [lysine 9] silencing the promoter of *Cyp7a1* was present in 3 week and 4 month offspring, alterations in histone methylation were not yet occurring in embryonic life [34]. However, the stage was beginning to be set as MPR-mediated decreases in the fetal expression of histone demethylases in the liver were apparent [34].

The more probable reason for indirect effects of a perinatal undernutrition and long-term alterations in hepatic gene expression is rapid postnatal catch-up growth. As previously mentioned, in humans postnatal catch-up growth can accelerate the onset and exacerbate the symptoms of metabolic disease in low birth weight children [25, 29–31]. Given the undernourished neonatal liver undergoes major catch-up growth postpartum, it is quite conceivable that the “stress” of active hepatocyte growth and replication during this period of time may confer detrimental metabolic deficits which only arise after this window of recovery. The leading mechanism likely involved in this rapid growth-triggered process is endoplasmic reticulum (ER) stress.

ER stress occurs when perturbation in the function or homeostasis of the ER leads to luminal accumulation of misfolded or unfolded proteins [64]. Many known triggers of ER stress include impaired disulfide bond formation, compromised Ca<sup>2+</sup> homeostasis, low amino acids, hypoxia, decreased N-linked glycosylation, increased lipid load, and greater oxidative stress. In response to ER stress, the unfolded protein response (UPR) tries to restore ER homeostasis by attenuating protein translation (i.e., increased pEIF2 $\alpha$ ) while at the same time increasing the expression of chaperone proteins involved in refolding proteins to alleviate the ER. However, if ER stress persists, apoptosis is initiated leading to alterations in gene expression and cell function. In MPR offspring with postnatal catch-up growth (due to restoration of proteins at weaning), the livers at 4 months exhibit ER stress (i.e., increased pEIF2 $\alpha$ ) attributed to impaired insulin sensitivity (e.g., decreased pAkt1[Ser473] despite the fact that the food intake is similar (Fig. 9.2, LP2) [63, 64]. Conversely, if there is no catch-up growth, protein translation is enhanced with higher hepatic insulin sensitivity (Fig. 9.2, LP1) [64]. The low-protein diet itself does not appear to be playing a direct role given alterations in the ER stress pathway were not detected in the fetal liver. Given oxidative stress is present in the undernourished liver, and that the “mismatch” in the nutritional environment likely leads to lipid overload and/or






**Fig. 9.2** The effect of maternal low-protein dietary regimes on hepatic phosphorylated eIF2 $\alpha$  (Ser51) protein levels at 4 months of age. The effect of (a) LP1 (low protein all life) and (b) LP2 (low-protein pregnancy and lactation) dietary regimes on phosphorylated protein kinase B (Akt1) at serine 473, Akt1, phosphorylated eukaryotic initiation factor 2  $\alpha$  (eIF2 $\alpha$ ) at serine 51, and eIF2 $\alpha$  protein levels in the livers of male offspring at postnatal day 130. Relative p-Akt1 (S473), Akt1, p-eIF2 $\alpha$  (S51), and eIF2 $\alpha$  protein levels were determined using Western blot analysis. Total protein was isolated and p-Akt1 (S473), Akt1, p-eIF2 $\alpha$  (S51), and eIF2 $\alpha$  protein were detected on a Western blot using p-Akt1 (S473), Akt1, p-eIF2 $\alpha$  (S51), and eIF2 $\alpha$  primary antibody. Their protein levels were quantified using densitometry and normalized to that of  $\beta$ -actin protein levels. Results were expressed as the mean  $\pm$  SEM. \*, significant difference ( $P < 0.05$ );  $n = 5-6$  for control and  $n = 6-7$  for LP1 and LP2 group, where each  $n$  represents a single offspring derived from a different mother (Reprinted from Sohi et al. [64], with permission from Elsevier Ltd.)

242 impaired disulfide bond formation, it is apparent that these triggers during perinatal life, coupled with  
 243 postnatal catch-up growth, may initiate the cascade leading to chronic ER stress [35, 47]. It is note-  
 244 worthy that in a perinatal rat model of nicotine exposure leading to postnatal catch-up growth and  
 245 dyslipidemia, ER stress was also evident in the adipose tissue of 6-month offspring [76]. Aside from  
 246 directly influencing hepatic gene expression and function, augmented ER stress in the liver may also  
 247 alter epigenetic mechanisms such as miRs. For example, activation of ER stress has been demon-  
 248 strated to induce miR-29a which is known to silence Igf-1 and pAkt-1 (Ser473) [75]. It is noteworthy  
 249 that miR-29a is increased in 4-month MPR offspring with catch-up growth and ER stress, coupled  
 250 with decreased Igf-1 and pAkt-1 (Ser473) [63, 64]. An overview of the direct and indirect mechanism  
 251 involved in the nutritional programming of the perinatal liver is illustrated in Fig. 9.3.

## 252 The “Plastic Liver”: Intervening in Early Life to Prevent 253 Long-Term Metabolic Dysfunction

254 From fetal to neonatal life, the liver undergoes extensive growth, differentiation, and remodeling cre-  
 255 ating an ideal window for intervention given its plasticity. During fetal life, the liver is considered  
 256 mainly hematopoietic, while in postnatal life is considered more hepatocyte-like [77]. This may  
 257 explain why certain perinatal nutritional insults altering postnatal gene expression are differentially  
 258 altered in fetal life [67, 72]. By mid-gestation in rodents, the liver bud is formed containing progenitor  
 259 cells that differentiate into either hepatocytes or ductal cells; however, in the last 3 days of gestation,



**Fig. 9.3** Overview of the direct and indirect mechanisms underlying how undernutrition in utero impairs liver function from neonatal to adult life. Direct pathways altered by maternal undernutrition are indicated by *red solid arrows*, while indirect pathways affected by placental insufficiency and postnatal catch-up growth are indicated by *red dashed arrows*. Neonatal intervention strategies are illustrated in *cyan arrows*

the liver mass triples due to extensive proliferation [78, 79]. After birth in rodents, there is a greater transition from fetal to adult hepatocytes accompanied by high rates of replication, neogenesis, and apoptosis [79]. The human liver develops in a similar pattern, although the majority of liver differentiation occurs in prenatal life [80]. It is estimated that the postnatal rodent liver at 3 weeks is equivalent to the human liver at the third trimester. Regardless of the species, the perinatal liver is undergoing extensive remodeling and is subject to alterations by environmental cues during this period. These cues can consist of alterations in nutrition, hormones/cell signaling, epigenetic forces, and/or by the actions of pharmaceuticals.

260  
261  
262  
263  
264  
265  
266  
267

268 From a nutrition standpoint, several studies have investigated the role of vitamins, folic acid,  
269 and proteins to reverse the effects of undernutrition on hepatic health. In a maternal diabetes model  
270 leading to IUGR and decreased liver weight in Sabra rats, supplementation of vitamins C and E in  
271 pregnancy prevented decreases in fetal liver weight, but not total bodyweight [81]. The IUGR-  
272 associated lipid peroxidation in these fetal livers was also significantly reduced due to maternal  
273 vitamin supplementation attributed to increases in superoxide dismutase antioxidant activity [81].  
274 Given its role a methyl donor for DNA methylation, intervention studies with folic acid show  
275 promise in reversing some of the epigenetic mechanisms associated with the undernourished liver.  
276 Elegant studies by Lillycrop demonstrated that administration of folic acid during MPR pregnancy  
277 reversed the decreases in DNA methylation to the promoters of *PPAR $\alpha$*  and *GR* and subsequently  
278 diminished the MPR increases in their fetal gene expression. But with respect to DNA methylation,  
279 the benefits of folic acid appear to be promoter specific given periconceptual intake of folic acid  
280 (400  $\mu\text{g}/\text{day}$ ) led to an increase in DNA methylation of hepatic insulin growth-like factor 2 and,  
281 subsequently, low birth weight [82]. As mentioned previously, introduction of a combination of  
282 nutrients (i.e., folic acid, vitamin B<sub>12</sub>) to the diet of IUGR offspring has multigenerational effects  
283 given the F2 generation did not exhibit impairments in hepatic and lipid homeostasis [48]. The use  
284 of the bile acid tauroursodeoxycholic acid (TUDCA) could be considered as a promising safe  
285 therapeutic agent in neonatal life given its ability to reduce ER stress (e.g., protein refolding) and  
286 consequentially improve liver insulin sensitivity [83]. With regard to protein supplementation, the  
287 beneficial effects of restoring maternal proteins also appear to be very promoter specific in the  
288 liver. In rats, restoring maternal proteins at birth prevents long-term decreases in hepatic chole-  
289 sterol metabolism (e.g., *Cyp7a1*) and *Igf-1* but leads to greater expression of genes involved in  
290 gluconeogenesis (e.g., *G6Pase* and *11 $\beta$ -HSD1*) [34, 63, 67]. These studies illustrate the complexity  
291 between the length of the nutritional insult, epigenetics, and catch-up growth on long-term hepatic  
292 gene expression.

293 Hormones and nuclear receptors have promise in reversing the adverse effects of undernutrition on  
294 hepatic dysfunction. One of the best examples is with the use of the glucagon-like peptide-1 (Glp-1)  
295 analog, exendin-4 (Ex-4). Neonatal administration of Ex-4 to uterine-ligated IUGR offspring pre-  
296 vented the long-term development of hepatic oxidative stress and insulin resistance [47]. It also  
297 exerted beneficial effects on the pancreatic  $\beta$  cells via increases in the expression of *Pdx-1* [84].  
298 Another hormone and antioxidant, melatonin, has been demonstrated in increase umbilical blood flow  
299 during gestation in sheep, but it did not rescue growth restriction in undernourished ewes [85].  
300 Targeting nuclear receptors may have a more sustained impact given their widespread roles in  
301 influencing endocrine function along with glucose and lipid homeostasis. Female IUGR offspring  
302 treated with agonists to the lipid-sensing nuclear receptor *PPAR $\gamma$*  have long-term insulin-sensitizing  
303 effects, although hypoglycemia was also exhibited [86]. Given the role of the liver X receptor (*LXR $\alpha$* )  
304 in regulating cholesterol, glucose, and fatty acid homeostasis, altering *LXR* activity in early life could  
305 impair several symptoms of the metabolic syndrome. A pilot study using the *LXR* agonist (GW3695)  
306 during neonatal life (PND5-15) in MPR offspring led to decreased total cholesterol levels concomi-  
307 tant with increased *LXR $\alpha$*  and *Cyp7a1* by 3 weeks of age [87]. An overview of the known neonatal  
308 interventions is summarized in Fig. 9.3.

309 Regardless of the success of particular intervention strategies in animal models, caution must be  
310 approached in assessing its overall efficacy. The intervention must be examined in the context of the  
311 species examined and how the timing of intervention relates to liver development (e.g., plasticity)  
312 between species. The impact of the intervention on epigenetic mechanisms must also be considered to  
313 determine its sustainability long-term but, more importantly, on the specificity (or lack thereof) to  
314 particular target promoters. For the time being, the safer approach may be in general dietary imple-  
315 mentation to reduce catch-up growth and the indirect burden it exerts on hepatic development and  
316 function.

## Conclusion

317

In response to maternal undernutrition and placental insufficiency, the fetal liver takes a huge hit with respect to development and growth. Consequentially, the undernourished neonatal liver has the most to gain in postnatal life leading to accelerated catch-up growth. However, both developmental events end up being detrimental to long-term liver function. The present review illustrates the direct epigenetic mechanisms underlying the aberrant expression of hepatic genes in malnourished offspring which persists into adulthood. Hypoxia in the neonatal liver also plays a role in driving some of these epigenetic mechanisms along with increased oxidative stress. With ensuing rapid catch-up growth in postnatal life, this places a burden on the normal growth trajectory of the liver leading to onset of ER stress. This culminates in further metabolic dysfunction such as ER-mediated insulin insensitivity in the liver. In this chapter, nutritional, hormonal, and pharmaceutical interventions early in life are cited which mitigate the effects of undernutrition on hepatic gene expression and function short- and long-term. However, further studies are warranted to address the safety, specificity, and sustainability of these interventions to the whole organism. Until that time, more conventional nutritional steps are necessary to reduce postnatal catch-up growth of IUGR offspring in the hope to reduce global effects (e.g., ER stress) on the recovering liver.

318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332

## References

333

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97(18):1837–47. 334  
335
2. Mathieu P, Pibarot P, Despres JP. Metabolic syndrome: the danger signal in atherosclerosis. *Vasc Health Risk Manag*. 2006;2(3):285–302. 336  
337
3. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. *Circulation*. 2010;121(7):e46–215. 338  
339
4. Lamarche B, Lemieux S, Dagenais GR, Despres JP. Visceral obesity and the risk of ischaemic heart disease: insights from the Quebec Cardiovascular Study. *Growth Hormon IGF Res Off J Growth Horm Res Soc Int Res Soc*. 1998;8(Suppl B(Journal Article)):1–8. 340  
341  
342
5. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. *Circulation*. 2008;117(19):2544–65. 343  
344  
345  
346  
347
6. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. *Circulation*. 2010;121(7):948–54. 348  
349
7. Mehal WZ, Iredale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. *Nat Med*. 2011;17(5):552–3. 350
8. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. *Clin Sci Lond Engl* 1979. 2007;112(5):265–80. 351  
352
9. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. *Clin Liver Dis*. 2004;8(3):521–33. viii. 353  
354
10. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatol Baltim Md*. 2006;44(4):865–73. 355  
356
11. Bhaskar ME. Management of cirrhosis and ascites. *N Engl J Med*. 2004;351(3):300–1. author reply 300–1. 357
12. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. *Hepatol Baltim Md*. 2010;52(3):934–44. 358  
359  
360
13. Ishimoto T, Lanaspá MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. *Hepatol Baltim Md*. 2013;58(5):1632–43. 361  
362
14. Nordestgaard BG, Bønn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA J Am Med Assoc*. 2007;298(3):299–308. 363  
364
15. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. *JAMA J Am Med Assoc*. 2007;298(3):309–16. 365  
366

- 367 16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic  
368 heart disease, and stroke: systematic review and meta-analysis. *BMJ*. 2003;326(7404):1423.
- 369 17. Barker DJ. The fetal and infant origins of adult disease. *BMJ*. 1990;301(6761):1111.
- 370 18. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH. Growth in utero and serum cholesterol concentrations in  
371 adult life. *BMJ*. 1993;307(6918):1524–7.
- 372 19. Valsamakis G, Kanaka-Gantenbein C, Malamitsi-Puchner A, Mastorakos G. Causes of intrauterine growth restric-  
373 tion and the postnatal development of the metabolic syndrome. *Ann N Y Acad Sci*. 2006;1092:138–47.
- 374 20. Neerhof MG. Causes of intrauterine growth restriction. *Clin Perinatol*. 1995;22(2):375–85.
- 375 21. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. *N Engl*  
376 *J Med*. 1976;295(7):349–53.
- 377 22. Desai M, Hales CN. Role of fetal and infant growth in programming metabolism in later life. *Biol Rev Camb Philos*  
378 *Soc*. 1997;72(2):329–48.
- 379 23. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose  
380 tolerance at age 64. *BMJ*. 1991;303(6809):1019–22.
- 381 24. McCance DR, Pettitt DJ, Hanson RL, Jacobsson LT, Knowler WC, Bennett PH. Birth weight and non-insulin  
382 dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? *BMJ*. 1994;308(6934):  
383 942–5.
- 384 25. Finken MJ, Inderson A, Van Montfoort N, Keijzer-Veen MG, van Weert AW, Carfil N, et al. Lipid profile and carotid  
385 intima-media thickness in a prospective cohort of very preterm subjects at age 19 years: effects of early growth and  
386 current body composition. *Pediatr Res*. 2006;59(4 Pt 1):604–9.
- 387 26. Ravelli AC, van der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, et al. Glucose tolerance in adults  
388 after prenatal exposure to famine. *Lancet*. 1998;351(9097):173–7.
- 389 27. Forsdahl A. Living conditions in childhood and subsequent development of risk factors for arteriosclerotic heart  
390 disease. The cardiovascular survey in Finnmark 1974–75. *J Epidemiol Community Health*. 1978;32(1):34–7.
- 391 28. Yudkin JS, Stanner S. Prenatal exposure to famine and health in later life. *Lancet*. 1998;351(9112):1361–2.
- 392 29. Yajnik C. Interactions of perturbations in intrauterine growth and growth during childhood on the risk of adult-onset  
393 disease. *Proc Nutr Soc*. 2000;59(2):257–65.
- 394 30. Eriksson JG. Early growth, and coronary heart disease and type 2 diabetes: experiences from the Helsinki Birth  
395 Cohort studies. *Int J Obes* 2005. 2006;30(Suppl 4(Journal Article)):S18–22.
- 396 31. Martin RM, McCarthy A, Smith GD, Davies DP, Ben-Shlomo Y. Infant nutrition and blood pressure in early adult-  
397 hood: the Barry Caerphilly growth study. *Am J Clin Nutr*. 2003;77(6):1489–97.
- 398 32. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis.  
399 *Diabetologia*. 1992;35(7):595–601.
- 400 33. Hales CN, Barker DJ. The thrifty phenotype hypothesis. *Br Med Bull*. 2001;60(Journal Article):5–20.
- 401 34. Sohi G, Marchand K, Revesz A, Arany E, Hardy DB. Maternal protein restriction elevates cholesterol in adult rat  
402 offspring due to repressive changes in histone modifications at the cholesterol 7 $\alpha$ -hydroxylase promoter. *Mol*  
403 *Endocrinol Baltim Md*. 2011;25(5):785–98.
- 404 35. Peterside IE, Selak MA, Simmons RA. Impaired oxidative phosphorylation in hepatic mitochondria in growth-  
405 retarded rats. *Am J Physiol Endocrinol Metab*. 2003;285(6):E1258–66.
- 406 36. Nevin CMY, Matuszewski B, R TRH, Richardson BS. Maternal nutrient restriction (MNR) in guinea pigs leads  
407 to fetal growth restricted (FGR) offspring with differential rates of organ catch-up growth. *Reprod Sci*. 2016; in  
408 revision. AU3
- 409 37. Deiber M, Chatelain P, Naville D, Putet G, Salle B. Functional hypersomatotropism in small for gestational age  
410 (SGA) newborn infants. *J Clin Endocrinol Metab*. 1989;68(1):232–4.
- 411 38. Singhal A, Cole TJ, Fewtrell M, Lucas A. Breastmilk feeding and lipoprotein profile in adolescents born preterm:  
412 follow-up of a prospective randomised study. *Lancet*. 2004;363(9421):1571–8.
- 413 39. Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood in subjects born with  
414 intrauterine growth retardation. *J Clin Endocrinol Metab*. 2000;85(4):1401–6.
- 415 40. Ross MG, Beall MH. Prediction of preterm birth: nonsonographic cervical methods. *Semin Perinatol*.  
416 2009;33(5):312–6.
- 417 41. Murotsuki J, Challis JR, Han VK, Fraher LJ, Gagnon R. Chronic fetal placental embolization and hypoxemia cause  
418 hypertension and myocardial hypertrophy in fetal sheep. *Am J Phys*. 1997;272(1 Pt 2):R201–7.
- 419 42. Ogata ES, Bussey ME, Finley S. Altered gas exchange, limited glucose and branched chain amino acids, and hypo-  
420 insulinism retard fetal growth in the rat. *Metabolism*. 1986;35(10):970–7.
- 421 43. Simmons RA, Gounis AS, Bangalore SA, Ogata ES. Intrauterine growth retardation: fetal glucose transport is  
422 diminished in lung but spared in brain. *Pediatr Res*. 1992;31(1):59–63.
- 423 44. Sarr O, Blake A, Thompson JA, Zhao L, Rabicki K, Walsh JC, et al. The differential effects of low birth weight and  
424 western diet consumption upon early life hepatic fibrosis development in guinea pig. *J Physiol*. 2015. AU4
- 425 45. Lane RH, Kelley DE, Gruetzmacher EM, Devaskar SU. Uteroplacental insufficiency alters hepatic fatty acid-  
426 metabolizing enzymes in juvenile and adult rats. *Am J Phys Regul Integr Comp Phys*. 2001;280(1):R183–90.

46. Simmons RA, Templeton LJ, Gertz SJ. Intrauterine growth retardation leads to the development of type 2 diabetes in the rat. *Diabetes*. 2001;50(10):2279–86. 427  
428
47. Raab EL, Vuguin PM, Stoffers DA, Simmons RA. Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. *Am J Phys Regul Integr Comp Phys*. 2009;297(6):R1785–94. 429  
430  
431
48. Goodspeed D, Seferovic MD, Holland W, Mcknight RA, Summers SA, Branch DW, et al. Essential nutrient supplementation prevents heritable metabolic disease in multigenerational intrauterine growth-restricted rats. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2015;29(3):807–19. 432  
433  
434
49. Baserga M, Hale MA, McKnight RA, Yu X, Callaway CW, Lane RH. Uteroplacental insufficiency alters hepatic expression, phosphorylation, and activity of the glucocorticoid receptor in fetal IUGR rats. *Am J Phys Regul Integr Comp Phys*. 2005;289(5):R1348–53. 435  
436  
437
50. Lane RH, Crawford SE, Flozak AS, Simmons RA. Localization and quantification of glucose transporters in liver of growth-retarded fetal and neonatal rats. *Am J Phys*. 1999;276(1 Pt 1):E135–42. 438  
439
51. Lane RH, MacLennan NK, Hsu JL, Janke SM, Pham TD. Increased hepatic peroxisome proliferator-activated receptor-gamma coactivator-1 gene expression in a rat model of intrauterine growth retardation and subsequent insulin resistance. *Endocrinology*. 2002;143(7):2486–90. 440  
441  
442
52. Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA. Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2009;23(8):2438–49. 443  
444
53. Zinkhan EK, Chin JR, Zalla JM, Yu B, Numpang B, Yu X, et al. Combination of intrauterine growth restriction and a high-fat diet impairs cholesterol elimination in rats. *Pediatr Res*. 2014;76(5):432–40. 445  
446
54. Zhang J, Lewis RM, Wang C, Hales N, Byrne CD. Maternal dietary iron restriction modulates hepatic lipid metabolism in the fetuses. *Am J Physiol Integr Comp Physiol*. 2005;288(1):R104–11. 447  
448
55. Elias AA, Ghaly A, Matuszewski B, Regnault TRH, Richardson BS. Maternal nutrient restriction in guinea pigs as an animal model for inducing fetal growth restriction. *Reprod Sci Thousand Oaks Calif*. 2015. 449  
450
56. Lumey LH. Compensatory placental growth after restricted maternal nutrition in early pregnancy. *Placenta*. 1998;19(1):105–11. 451  
452
57. Sohlström A, Katsman A, Kind KL, Roberts CT, Owens PC, Robinson JS, et al. Food restriction alters pregnancy-associated changes in IGF and IGFBP in the guinea pig. *Am J Phys*. 1998;274(3 Pt 1):E410–6. 453  
454
58. Tosh DN, Fu Q, Callaway CW, McKnight RA, McMillen IC, Ross MG, et al. Epigenetics of programmed obesity: alteration in IUGR rat hepatic IGF1 mRNA expression and histone structure in rapid vs. delayed postnatal catch-up growth. *Am J Physiol Gastrointest Liver Physiol*. 2010;299(5):G1023–9. 455  
456  
457
59. Nijland MJ, Mitsuya K, Li C, Ford S, McDonald TJ, Nathanielsz PW, et al. Epigenetic modification of fetal baboon hepatic phosphoenolpyruvate carboxykinase following exposure to moderately reduced nutrient availability. *J Physiol*. 2010;588(Pt 8):1349–59. 458  
459  
460
60. George LA, Zhang L, Tuersunjiang N, Ma Y, Long NM, Uthlaut AB, et al. Early maternal undernutrition programs increased feed intake, altered glucose metabolism and insulin secretion, and liver function in aged female offspring. *Am J Phys Regul Integr Comp Phys*. 2012;302(7):R795–804. 461  
462  
463
61. Petry CJ, Ozanne SE, Hales CN. Programming of intermediary metabolism. *Mol Cell Endocrinol*. 2001;185(1–2):81–91. 464  
465
62. Crosby WM. Studies in fetal malnutrition. *Am J Dis Child* 1960. 1991;145(8):871–6. 466
63. Sohi G, Revesz A, Ramkumar J, Hardy DB. Higher hepatic miR-29 expression in undernourished male rats during the postnatal period targets the long-term repression of IGF-1. *Endocrinology*. 2015;156(9):3069–76. 467  
468
64. Sohi G, Revesz A, Hardy DB. Nutritional mismatch in postnatal life of low birth weight rat offspring leads to increased phosphorylation of hepatic eukaryotic initiation factor 2  $\alpha$  in adulthood. *Metabolism*. 2013;62(10):1367–74. 469  
470
65. Guan H, Arany E, van Beek JP, Chamson-Reig A, Thyssen S, Hill DJ, et al. Adipose tissue gene expression profiling reveals distinct molecular pathways that define visceral adiposity in offspring of maternal protein-restricted rats. *Am J Physiol Metab*. 2005;288(4):E663–73. 471  
472
66. Petrik J, Reusens B, Arany E, Remacle C, Coelho C, Hoet JJ, et al. A low protein diet alters the balance of islet cell replication and apoptosis in the fetal and neonatal rat and is associated with a reduced pancreatic expression of insulin-like growth factor-II. *Endocrinology*. 1999;140(10):4861–73. 473  
474  
475
67. Vo T, Revesz A, Ma N, Hardy DB. Maternal protein restriction leads to enhanced hepatic gluconeogenic gene expression in adult male rat offspring due to impaired expression of the liver x receptor. *J Endocrinol*. 2013;218(Journal Article):85–97. 476  
477  
478
68. Chamson-Reig A, Thyssen SM, Hill DJ, Arany E. Exposure of the pregnant rat to low protein diet causes impaired glucose homeostasis in the young adult offspring by different mechanisms in males and females. *Exp Biol Med Maywood NJ*. 2009;234(12):1425–36. 479  
480  
481
69. Petry CJ, Ozanne SE, Wang CL, Hales CN. Early protein restriction and obesity independently induce hypertension in 1-year-old rats. *Clin Sci Lond Engl* 1979. 1997;93(2):147–52. 482  
483
70. Burns SP, Desai M, Cohen RD, Hales CN, Iles RA, Germain JP, et al. Gluconeogenesis, glucose handling, and structural changes in livers of the adult offspring of rats partially deprived of protein during pregnancy and lactation. *J Clin Invest*. 1997;100(7):1768–74. 484  
485  
486

- 487 71. Ozanne SE, Smith GD, Tikerpae J, Hales CN. Altered regulation of hepatic glucose output in the male offspring of  
488 protein-malnourished rat dams. *Am J Phys.* 1996;270(4 Pt 1):E559–64.
- 489 72. Sohi G, Barry EJ, Velenosi TJ, Urquhart BL, Hardy DB. Protein restoration in low-birth-weight rat offspring derived  
490 from maternal low-protein diet leads to elevated hepatic CYP3A and CYP2C11 activity in adulthood. *Drug Metab*  
491 *Dispos Biol Fate Chem.* 2014;42(2):221–8.
- 492 73. Elias AA, M B, Zhao L, N K, Regnault TRH, R BS. Maternal nutrient restriction in guinea pigs leads to fetal growth  
493 restriction with evidence for chronic hypoxia. *Am J Physiol.* in revision (n.d).
- 494 74. Fu Q, McKnight RA, Callaway CW, Yu X, Lane RH, Majnik AV. Intrauterine growth restriction disrupts develop-  
495 mental epigenetics around distal growth hormone response elements on the rat hepatic IGF-1 gene. *FASEB J Off*  
496 *Publ Fed Am Soc Exp Biol.* 2015;29(4):1176–84.
- 497 75. Nolan K, Mitchem MR, Jimenez-Mateos EM, Henshall DC, Concannon CG, Prehn JH. Increased expression of  
498 microRNA-29a in ALS mice: functional analysis of its inhibition. *J Mol Neurosci MN.* 2014;53(2):231–41.
- 499 76. Barra NG, VanDuzer T, Holloway AC, Hardy DB. Maternal nicotine exposure (MNE) leads to decreased visceral  
500 adipocyte size associated with endoplasmic reticulum (ER) stress in 26 week old rat offspring. *Reprod Sci.* 2016;  
501 accepted.
- 502 77. Gualdi R, Bossard P, Zheng M, Hamada Y, Coleman JR, Zaret KS. Hepatic specification of the gut endoderm  
503 in vitro: cell signaling and transcriptional control. *Genes Dev.* 1996;10(13):1670–82.
- 504 78. Cascio S, Zaret KS. Hepatocyte differentiation initiates during endodermal-mesenchymal interactions prior to liver  
505 formation. *Dev Camb Engl.* 1991;113(1):217–25.
- 506 79. Greengard O, Federman M, Knox WE. Cytomorphometry of developing rat liver and its application to enzymic  
507 differentiation. *J Cell Biol.* 1972;52(2):261–72.
- 508 80. Kung JWC, Currie IS, Forbes SJ, Ross JA. Liver development, regeneration, and carcinogenesis. *J Biomed*  
509 *Biotechnol.* 2010;2010:984248.
- 510 81. Ornoy A, Tsadok MA, Yaffe P, Zangen SW. The Cohen diabetic rat as a model for fetal growth restriction:  
511 vitamins C and E reduce fetal oxidative stress but do not restore normal growth. *Reprod Toxicol Elmsford N.*  
512 2009;28(4):521–9.
- 513 82. Steegers-Theunissen RP, Obermann-Borst SA, Kremer D, Lindemans J, Siebel C, Steegers EA, et al. Periconceptual  
514 maternal folic acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young  
515 child. *PLoS One.* 2009;4(11):e7845.
- 516 83. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, et al. Tauroursodeoxycholic acid may improve  
517 liver and muscle but not adipose tissue insulin sensitivity in obese men and women. *Diabetes.* 2010;59(8):1899–905.
- 518 84. Pinney SE, Jaecle Santos LJ, Han Y, Stoffers DA, Simmons RA. Exendin-4 increases histone acetylase activity  
519 and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat. *Diabetologia.*  
520 2011;54(10):2606–14.
- 521 85. Lemley CO, Meyer AM, Camacho LE, Neville TL, Newman DJ, Caton JS, et al. Melatonin supplementation alters  
522 uteroplacental hemodynamics and fetal development in an ovine model of intrauterine growth restriction. *Am*  
523 *J Physiol Integr Comp Physiol.* 2012;302(4):R454–67.
- 524 86. Garg M, Thamotharan M, Pan G, Lee PW, Devaskar SU. Early exposure of the pregestational intrauterine and  
525 postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor- $\gamma$  agonist. *Am*  
526 *J Physiol Metab.* 2010;298(3):E489–98.
- 527 87. Sohi G, Revesz A, Arany E, Hardy DB. The liver X receptor mediates the impaired cholesterol metabolism exhib-  
528 ited in the offspring of maternal protein restricted rats. *Reprod Sci.* 2011;18(4):F163.